Related references
Note: Only part of the references are listed.Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
A. Gallardo et al.
BRITISH JOURNAL OF CANCER (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer
Sheng Chen et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Michael Untch et al.
LANCET ONCOLOGY (2012)
Expression of pERK and pAKT in pediatric high grade astrocytomas: Correlation with YKL40 and prognostic significance
Manila Antonelli et al.
NEUROPATHOLOGY (2012)
High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients
Chandra Bartholomeusz et al.
ONCOLOGIST (2012)
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Peter A. Fasching et al.
BMC CANCER (2011)
Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer
T. Tanei et al.
EJSO (2011)
A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors
Zaina Sangale et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2011)
Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy
Neil K. Taunk et al.
RADIOTHERAPY AND ONCOLOGY (2010)
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
S. Gori et al.
ANNALS OF ONCOLOGY (2009)
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Robin L. Jones et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
F. Andre et al.
ANNALS OF ONCOLOGY (2008)
Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer
Duygu Derin et al.
CANCER INVESTIGATION (2008)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis
Chad J. Creighton et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
Alessandra Gennari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
HER2/neu in systemic therapy for women with breast cancer:: a systematic review
Bindi Dhesy-Thind et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol
Veronique Gagnon et al.
APOPTOSIS (2008)
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-IIIbreast cancer
Cornelia Liedtke et al.
BREAST CANCER RESEARCH (2008)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
KI Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
